Robert (Bob) Ezzell joined atai Life Sciences in 2021.
Previously Bob was Director of Regulatory Affairs at Glympse Bio where he led the approval of
Previously Bob was Director of Regulatory Affairs at Glympse Bio where he led the approval of synthetic protease activity sensors used in immuno-oncology and liver disease (NASH, NAFLD) indications.
Prior to that, he held Regulatory and Quality positions at Sanofi, Onduo (Sanofi-Google Digital Health joint venture), and Philips. Before that Bob was Director of Product Development at RenaMed Biologics, which had a combination product in clinical trials to treat acute renal failure. Prior to joining RenaMed, he held senior positions at Argose (minimal invasive glucose monitoring) and was a founding Scientist at Molecular Geodesics (MGI). Before MGI, Bob was an Assistant Professor at Harvard Medical School.
Bob holds a Ph.D. in Cell and Molecular Biology from UC Berkeley, and has Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).